Strategies to Enhance the Intravenous Treatment Satisfaction and Drug Safety Awareness Among Patients with Multiple Sclerosis in Macedonia

References

1. Hutchinson M, et al. Intravenous therapy for the treatment of multiple sclerosis. Future Prescriber 2008; Volume 8(1): 15.10.1002/fps.4
Search in Google Scholar Back to article
2. Weinshenker BG, et al. The natural history of multiple sclerosis: a geographic based study. I. Clinical course and disability. Brain. 1989 Feb; 112 (Pt 1): 133-46.10.1093/brain/112.1.133
Search in Google Scholar Back to article
3. Cree B. Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 2006; 12: 171–178.10.1097/01.nrl.0000204859.15501.6b
Open DOI Search in Google Scholar Back to article
4. Hohlfeld R, Wekerle H. Drug Insight: using monoclonal antibodies to treat multiple sclerosis. Nat Clin Pract Neurol 2005; 1: 34–44.10.1038/ncpneuro0016
Search in Google Scholar Back to article
5. Jakimovski D, et al. Interferon β for Multiple Sclerosis. Cold Spring Harb Perspect Med 2018 Jan 8. (Epub ahead of print).10.1101/cshperspect.a032003
Search in Google Scholar Back to article
6. Patti F, Optimizing the benefits of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence. 2010 Feb; 4: 1-9.10.2147/PPA.S8230
Search in Google Scholar Back to article
7. Frohman E, et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist. 2002 Jul; 8(4): 227-36.10.1097/00127893-200207000-00003
Open DOI Search in Google Scholar Back to article